Abstracts tagged "endothelial cells"

Abstract Number: 764 • 2014 ACR/ARHP Annual Meeting
ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary Complications
Rong Han and Maria Trojanowska, Arthritis Center, Boston University, Boston, MA
Background/Purpose: Pulmonary arterial hypertension (PAH) and pulmonary fibrosis (PF) are the two major lung complications associated with the autoimmune disease systemic sclerosis (SSc), and constitute…
Abstract Number: 3003 • 2014 ACR/ARHP Annual Meeting
Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells, and Immune Cells
Tetsuo Toyama¹, Yoshihide Asano¹, Takehiro Takahashi¹, Ryosuke Saigusa¹, Yohei Ichimura¹, Takashi Taniguchi¹, Shinji Noda¹, Kaname Akamata¹, Shinichi Sato¹, Takafumi Kadono¹ and Koichi Shudo², ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Reseach Foundation ITSUU Laboratory, Tokyo, Japan
Background/Purpose: Am80 is a synthetic retinoid serving as an agonist for retinoic acid receptor α/β with chemical and pharmacological advantages over all-trans retinoic acid, such…
Abstract Number: 2445 • 2014 ACR/ARHP Annual Meeting
A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro
Javier Rodríguez-Carrio¹, Mercedes Alperi-López², Patricia López¹, Sara Alonso-Castro², Santiago Rubén Carro-Esteban¹, Javier Ballina-García² and Ana Suárez¹, ¹Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ²Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
Background/Purpose Cell-derived microparticles (MPs) could be considered biomarkers of cell damage and activation and they are thought to have a role in cardiovascular (CV) and inflammatory…
Abstract Number: 1980 • 2014 ACR/ARHP Annual Meeting
Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels
Markos Patsouras¹, Marina Sikara², Athanasios G. Tzioufas² and Panayiotis Vlachoyiannopoulos², ¹PATHOPHYSIOLOGY DEPARTMENT, UNIVERSITY OF ATHENS, School of Medicine, National University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose Antiphospholipid syndrome (APS) is an acquired thombophillia characterized by recurrent thromboembolism and pregnancy morbidity. Thrombospondin (TSP-1) is a matricellular glycoprotein with antiangiogenic and proapoptotic…
Abstract Number: 1717 • 2014 ACR/ARHP Annual Meeting
Endothelial to Mesenchymal Transition Contributes to the Development of Pulmonary Vasculopathy in Systemic Sclerosis PAH
Robert Good¹, Adrian Gilbane², Sarah Trinder², David Abraham³, Christopher Denton³ and Alan M. Holmes⁴, ¹Rheumatology and Connective Tissue Diseases, UCL, LONDON, United Kingdom, ²Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom, ³Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom
Background/Purpose Vascular complications in Scleroderma (SSc) patients are associated with high mortality, particularly in patients who develop pulmonary arterial hypertension (SSc-PAH). Vascular complications, thought to…
Abstract Number: 1704 • 2014 ACR/ARHP Annual Meeting
CXCL4 Promotes Fibrosis By Increasing Expression of Extracellular Matrix Modifying Factors and By Facilitating Epithelial/Endothelial Mesenchymal Transition
W. Marut¹, A.J. Affandi¹, A. Limpers¹ and T.R.D.J. Radstake², ¹Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Systemic sclerosis (SSc) is a degenerative disorder, characterized by vascular abnormalities and immunological disturbances followed by excessive fibrosis in multiple organ systems. In a…
Abstract Number: 1720 • 2014 ACR/ARHP Annual Meeting
GATA6 Deficiency Activates UPR Pathways in Endothelial Cells during the Development of Pulmonary Arterial Hypertension
Rong Han¹, Rosanne Van Deuren², Stefania Lenna¹, Izabela Chrobak¹, Timothy Radstake³, Carol Feghali-Bostwick⁴ and Maria Trojanowska¹, ¹Arthritis Center, Boston University, Boston, MA, ²Rheumatology Department, University Medical Center Nijmegen, Nijmegen, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medical University of South Carolina, Charleston, SC
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe lung complication of systemic sclerosis (SSc), and accounts for a large proportion of SSc-related deaths. As a…
Abstract Number: 780 • 2014 ACR/ARHP Annual Meeting
Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis
Rie Karasawa¹, Paul A. Monach², Mayumi Tamaki¹, Takahiro Okazaki³, Masamichi Oh-Ishi⁴, Yoshio Kodera⁴, Toshiko Sato¹, Shoichi Ozaki⁵, Kaiyu Jiang⁶, Kazuo Yudoh¹, James N. Jarvis⁷ and Peter A. Merkel⁸, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴School of Science, Kitasato University, Sagamihara, Japan, ⁵Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶415 Carmen Road, Apt. 1, The University at Buffalo, Buffalo, NY, ⁷Pediatrics, The University at Buffalo, Buffalo, NY, ⁸Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose �:The mechanisms of the blood vessel injury in giant cell arteritis (GCA), a systemic vasculitis characterized by inflammation of large- and medium-sized vessels, remain…
Abstract Number: 2565 • 2013 ACR/ARHP Annual Meeting
Synergistic Effects Of Endothelin-1 On Transforming Growth Factor-β1 (TGF-β1) Induced Endothelial-To-Mesenchymal Transition. A Novel Mechanism For The Fibrogenic Effects Of Endothelin
Peter J. Wermuth, Zhaodong Li and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The process of endothelial-to-mesenchymal transition (EndoMT) may be a crucial pathway in the generation of activated myofibroblasts, cells that play a pivotal role in…
Abstract Number: 2560 • 2013 ACR/ARHP Annual Meeting
Analysis Of Global Gene Expression Of Pulmonary Endothelial Cells From Caveolin-1 Knock-Out Mice
Sonsoles Piera-Velazquez¹, Zhaodong Li¹, Sankar Addya², Peter J. Wermuth¹ and Sergio A. Jimenez¹, ¹Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA, ²Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Caveolin-1 (Cav-1) deficiency has recently been shown to participate in the pathogenesis of tissue fibrosis in Systemic Sclerosis (SSc). Although the mechanisms involved have…
Abstract Number: 2527 • 2013 ACR/ARHP Annual Meeting
Association Of Nail Dystrophy With Capillaroscopic Abnormalities, Anti-Endothelial Cell Antibody, Endothelin-1, Activity and Chronicity In Systemic Lupus Erythematosus
Violeta Higuera¹, Luis M. Amezcua-Guerra², Felipe Massó³, Mariana Patlan⁴, Hugo Montoya⁵, Araceli Paez⁴ and Luis H. Silveira⁶, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁴Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁶Rheumatology, Instituto Nacional Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, characterized by a broad spectrum of clinical manifestations. There is a large…
Abstract Number: 1373 • 2013 ACR/ARHP Annual Meeting
Connective Tissue Growth Factor Promotes Angiogenesis Through Increased Notch-1 Signaling in Rheumatoid Arthritis
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Kazuhisa Iwabuchi², Mitsuaki Yanagida², Keigo Ikeda³, Shinji Morimoto⁴, Yoshinari Takasaki⁵ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan
Background/Purpose: Increased angiogenesis has been associated with various inflammatory disease states including rheumatoid arthritis (RA), and it has been considered as one of main factors…
Abstract Number: 937 • 2013 ACR/ARHP Annual Meeting
Inhibitor Of DNA Binding 1 Mediates Angiogenesis In Rheumatoid Arthritis By Recruitment Of Endothelial Progenitor Cells
Takeo Isozaki¹, Alisa E. Koch², M. Asif Amin¹, Ali S. Arbab³, Gautam Edhayan⁴, Christine M. Ha⁴, Pei-Suen Tsou⁴, Sean C. Friday⁴, David A. Fox⁴ and Jeffrey H. Ruth⁴, ¹Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²University of Michigan Medical School, Ann Arbor, MI, ³Diagnostic Radiology, Henry Ford Hospital and Medical Centers, Detroit, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Endothelial progenitor cells (EPCs) are known to induce vasculoproliferative responses within rheumatoid arthritis (RA) synovial tissue (ST). Inhibitor of DNA-Binding 1 (Id1) is a…
Abstract Number: 694 • 2013 ACR/ARHP Annual Meeting
Peripheral Bone Marrow-Derived Endothelial Progenitor Cells and N-Terminal Probrain Natriuretic Peptide in Scleroderma Mexican Patients With and Without Diastolic Dysfunction: A Preliminary Report
Jesús Sepúlveda^1,2, Olga Vera-Lastra³, Maria Pilar Cruz-Dominguez⁴, Laura Montiel-Cervantes⁵, Joaquín Gómez-León⁶, Luis Robles-Espinoza⁷, Ramón Lozano-Morales⁷, Sergio Mendoza-Alvarez¹, Rubiraida Molina-Aguilar⁵, Gabriela Medina⁸, Jorge Vela-Ojeda⁹ and Luis J. Jara¹⁰, ¹Internal Medicine, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ²Unidad de Estudios de Posgrado, Universidad Nacional Autónoma de México, Mexico City, Mexico, ³Internal Medicine, MD, Mexico City, Mexico, ⁴Division of Research, Hospital de Especialidades Centro Medico Nacional La Raza., Mexico, DF, Mexico, ⁵Hematology Laboratory, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁶Cardiology Department, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁷Central Laboratory, Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸CMN La Raza IMSS, Seris/Zachila s/n La Raza, Mexico City, Mexico, ⁹Instituto Mexicano del Seguro Social, Mexico City, Mexico, ¹⁰Research and Education, Hospital de Especialidades Centro Medico La Raza, México City, Mexico
Background/Purpose: Diastolic dysfunction (DD) in systemic sclerosis (SSc) is a marker of increased risk of death. The N-terminal pro-brain natriuretic peptide (NT-proBNP) is a neurohormone…
Abstract Number: 631 • 2013 ACR/ARHP Annual Meeting
Type I IFN Regulation Of IL-10 Is Detrimental To Endothelial Cell Differentiation and May Enhance Cardiovascular Risk In Systemic Lupus Erythematosus
J. Michelle Kahlenberg¹, Alyssa Cates², Victoria Holden³, Carolyne K. Smith⁴ and Mariana J. Kaplan⁵, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Pathology, University of Michigan, Ann Arbor, MI, ⁴Rheumatology and Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, ⁵Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease resulting in organ damage and an elevated risk of cardiovascular disease (CVD). Previous reports have suggested…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].